

27 March 2024

## Q1 Revenue Update

### Highlights:

- **Total unaudited FY24 (ending 31 December 2024) revenues through February 2024 of \$3.1m**
- **Ongoing results follow total unaudited group revenue from all operations of \$21.6m in FY23 (up 148% on FY22: \$8.7m)**
- **FY23 was third consecutive record revenue year for the Company**

**Melodiol Global Health Limited (ASX:ME1) ('Melodiol' or 'the Company')** is pleased to advise that it has generated unaudited revenues of \$3.1m through February 2024.

These revenues include results from Mernova Medicinal, the Company's recreational cannabis division in Canada, as well as Health House International, which distributes medical cannabis in Australia and other medical products in Europe.

Mernova's unaudited revenue through February totals \$1.45m, been driven by ongoing sales of its high quality, 'Ritual' branded products across a variety of Canadian markets. Mernova currently has confirmed POs for March revenue of \$272,000 and continues to witness strong demand across the Canadian recreational cannabis marketplace. Health House International contributed \$1.7m of sales for the two months ending in February and continues to be a key component of the Company's revenue mix.

As previously announced, the Company has rationalised its portfolio to focus on these revenue generating units in order to accelerate its strategic objective of reaching a cash flow positive state and will provide further updates on revenue when available.

### Management commentary:

**CEO and Managing Director, Mr William Lay said:** *"We continue to be very proud of the work being done at our core subsidiaries to build a strong revenue base that supports our strategic objectives. All of our internal teams continue to work diligently towards expanding this revenue base, and we look forward to providing further updates in due course."*

-Ends-

### Authority and Contact Details

This announcement has been authorised for release by the Disclosure Committee of Melodiol Global Health Limited.

For further information, please contact:

### Investor Enquiries

Melodiol Global Health Limited

E: [info@cresopharma.com](mailto:info@cresopharma.com)

P: +61 (0) 497 571 532

### About Melodiol

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops

cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: <https://melodiolglobalhealth.com/>

**Melodiol offices:**

**Australia:** Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

**Canada:** 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

**Forward Looking statements**

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition.

These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.